MK-2870 is an investigational medication being studied for its potential to treat gastrointestinal cancers. It is being tested both as a standalone treatment and in combination with other anticancer agents. The main goal of the study is to assess the safety and effectiveness of MK-2870 in shrinking tumors or stopping their growth.

Colorectal Cancer – This is a type of cancer that begins in the colon or rectum, parts of the large intestine. It often starts as small, noncancerous clumps of cells called polyps that can develop into cancer over time. As the disease progresses, it can invade nearby tissues and spread to other parts of the body. Symptoms may include changes in bowel habits, blood in the stool, and abdominal discomfort. The progression can vary, with some cases remaining localized while others spread more aggressively.

Pancreatic Ductal Adenocarcinoma – This is a common type of pancreatic cancer that originates in the ducts of the pancreas. It tends to grow and spread quickly, often reaching nearby organs and distant sites in the body. Early stages may not show symptoms, but as it progresses, it can cause jaundice, weight loss, and abdominal pain. The disease can obstruct the bile duct, leading to digestive issues. Its progression is often aggressive, making early detection challenging.

Biliary Tract Cancer – This cancer affects the bile ducts, which are responsible for carrying bile from the liver to the small intestine. It can develop in any part of the bile duct system and may cause symptoms like jaundice, itching, and abdominal pain as it progresses. The disease can obstruct bile flow, leading to liver damage and digestive problems. It often spreads to nearby organs and tissues, complicating its progression.